New Zealand markets closed

Ocular Therapeutix, Inc. (OCUL)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
5.48+0.02 (+0.37%)
At close: 04:00PM EDT
5.11 -0.37 (-6.75%)
After hours: 07:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close5.46
Open5.54
Bid5.10 x 2900
Ask5.60 x 1400
Day's range5.38 - 5.63
52-week range2.91 - 12.50
Volume567,716
Avg. volume579,679
Market cap420.643M
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Business Wire

    Ocular Therapeutix™ to Present at the H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference

    BEDFORD, Mass., August 10, 2022--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will present at the H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference on Wednesday, August 17, 2022:

  • Business Wire

    Ocular Therapeutix™ Reports Second Quarter 2022 Financial Results and Business Update

    BEDFORD, Mass., August 08, 2022--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today reported financial results for the quarter ended June 30, 2022, and provided updates on its ophthalmology pipeline.

  • Business Wire

    Ocular Therapeutix™ To Report Second Quarter 2022 Financial Results

    BEDFORD, Mass., July 25, 2022--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will report second quarter ended June 30, 2022 financial results after the close on Monday, August 8, 2022. Following distribution of the earnings release via wire services, the Ocular Therapeutix management team will host a live conference call and